Key Lessons & Opportunities in applying NCA and PopPK to ADCs
Applying NCA and PopPK to ADCs helps decode complex PK, balance DAR effects, and guide…
CertaraOctober 24, 2025
Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
Danielle PillsburyOctober 15, 2025
Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns
US (ET): Thursday, November 6, 11:00am – 11:30am EMEA (GMT): Thursday, November 13, 10:00am –…
Danielle PillsburyOctober 10, 2025
Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer
Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…
CertaraOctober 2, 2025
Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science
Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…
CertaraSeptember 22, 2025
